Amedisys (AMED) PT Raised to $125 at Cantor Fitzgerald
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $114.95 --0%
Rating Summary:
13 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 19 | New: 10
Rating Summary:
13 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 19 | New: 10
Trade Now!
Join SI Premium – FREE
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Cantor Fitzgerald analyst Joseph France raised the price target on Amedisys (NASDAQ: AMED) to $125.00 (from $117.00) while maintaining a Neutral rating. Cantor Fitzgerald increased 2019 estimates to reflect the accretive impact of the Compassionate Care acquisition on AMED's earnings.
Cantor Fitzgerald raised 2019 revenue estimate to $1.93 billion (from $1.75 billion), 2019 adjusted EBITDA estimate to $211 million (from $189 million), and 2019 adjusted EPS estimate to $4.05 (from $3.85).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Splunk (SPLK) Beats and Raises but PT Drops to $145 at BofA Securities on Multiple Compression
- UPDATE: Snowflake Inc. (SNOW) PT Lowered to $175 at Deutsche Bank
- Cranswick Plc. (CWK:LN) PT Lowered to GBP40 at Berenberg
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Cantor Fitzgerald, Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
